IntegraGen, Pompidou Hospital Collaborate
News Jul 10, 2015
Clinicians and biologists at the hospital will use the new methods along with bioinformatic analysis techniques jointly developed by the partners in order to rapidly interpret genomic data. The technologies will enable patients, particularly those with cancer tumors, to be rapidly prescribed targeted therapies, IntegraGen and HEGP said.
The deal will allow oncologists and biologists at Paris-based HEGP to "benefit from the latest genome sequencing technologies and … to develop specific tools for interpreting results which enable the personalized care of patients," Pierre Laurent-Puig, an oncology biologist at the hospital, said in a statement. "This will result in a better ability to diagnose and treat each patient on an individual basis, depending on the genetic markers identified in their tumor."
HEGP operates under the aegis of the public hospital system of the city of Paris and its suburbs.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE